About 15,300 results
Open links in new tab
  1. Homepage | RMD Open | A leading rheumatology journal from …

    RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation.Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.

  2. Authors | RMD Open | A leading rheumatology journal from …

    RMD Open is an open access journal and levies an Article Processing Charge (APC) of 2,275 GBP (exclusive of VAT for UK and EU authors). The APC for Letters is 1,140 GBP. There are no submission, colour or page charges. There is a 25% discount for articles where the corresponding author has reviewed for RMD Open within the previous 12 months. A 50% discount on the standard APC will apply to ...

  3. About | RMD Open | A leading rheumatology journal from EULAR …

    Web of Science Core Collection: Science Citation Index Expanded; Emerging Sources Citation Index, Current Contents: Clinical Medicine, MEDLINE (Index Medicus), PubMed Central, Scopus, Embase (Excerpta Medica), DOAJ, Google Scholar

  4. Daratumumab for autoimmune diseases: a systematic review

    Methods. A systematic review of the literature according to the Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines19 was conducted. Two databases (MEDLINE via PubMed, Embase via Ovid) were searched on the 16 March 2023 (updated search on 10 June 2023, on 9 September 2023 and 6 November 2023) to identify case reports and case series reporting the use of daratumumab in ...

  5. Entry point of machine learning in axial spondyloarthritis

    Axial spondyloarthritis (axSpA) is a globally prevalent and challenging autoimmune disease. Characterised by insidious onset and slow progression, the absence of specific clinical manifestations and biomarkers often leads to misdiagnosis, thereby complicating early detection and diagnosis of axSpA. Furthermore, the high heterogeneity of axSpA, its complex pathogenesis and the lack of specific ...

  6. Fibromyalgia: a new facet of the post-COVID-19 syndrome …

    Objective Postacute COVID-19 syndrome (PACS) is an emerging entity characterised by a large array of manifestations, including musculoskeletal complaints, fatigue and cognitive or sleep disturbances. Since similar symptoms are present also in patients with fibromyalgia (FM), we decided to perform a web-based cross-sectional survey aimed at investigating the prevalence and predictors of FM in ...

  7. Evaluating the efficacy of biologics with and without methotrexate …

    Introduction An important consideration in the treatment of patients with psoriatic arthritis (PsA) is whether the addition of methotrexate (MTX) to biologics has greater efficacy than biologic monotherapy with respect to efficacy outcomes in these patients. Objectives To conduct a network meta-analysis (NMA) comparing biologics by treatment class with and without MTX for treatment of adults ...

  8. Health technology assessment: a framework | RMD Open

    In a time where there is growing pressure on healthcare budgets, there is increased scrutiny of new health technologies, their effectiveness, safety and costs.1 It is in this context that Health Technology Assessment (HTA) has become increasingly important. The purpose of HTA is to provide policymakers with evidence to inform decision-making and develop guidance on the reimbursement and ...

  9. Hydroxychloroquine and the risk of respiratory infections among …

    Objectives To determine the effect of hydroxychloroquine on the incidence of new respiratory infections in a large registry of rheumatoid arthritis (RA) patients compared with a matched cohort receiving other conventional disease-modifying antirheumatic drugs (csDMARDs). Methods We reviewed physician-reported infections including upper respiratory infections (URI), bronchitis and pneumonia in ...

  10. Viewpoint on anifrolumab in patients with systemic lupus …

    Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterised by unpredictable flares. Many patients with SLE are unable to achieve the recommended treatment goal of remission or the intermediate, yet still clinically beneficial, goal of Lupus Low Disease Activity State (LLDAS) with standard of care (SoC) treatments. LLDAS is an emerging treat-to-target goal in SLE ...